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Abstract
Background: Class I histone deacetylases (HDACs) have been reported to be overexpressed in clear cell renal cell
carcinoma (ccRCC), whereas the expression of class II HDACs is unknown.
Methods: Four isogenic cell lines C2/C2VHL and 786-O/786-OVHL with differential VHL expression are used in our
studies. Cobalt chloride is used to mimic hypoxia in vitro. HIF-2α knockdowns in C2 and 786-O cells is used to
evaluate the effect on HDAC 1 expression and activity. Invasion and migration assays are used to investigate the
role of HDAC 1 and HDAC 6 expression in ccRCC cells. Comparisons are made between experimental groups using
the paired T-test, the two-sample Student’s T-test or one-way ANOVA, as appropriate. ccRCC and the TCGA dataset
are used to observe the clinical correlation between HDAC 1 and HDAC 6 overexpression and overall and
progression free survival.
Results: Our analysis of tumor and matched non-tumor tissues from radical nephrectomies showed overexpression
of class I and II HDACs (HDAC6 only in a subset of patients). In vitro, both HDAC1 and HDAC6 over-expression
increased cell invasion and motility, respectively, in ccRCC cells. HDAC1 regulated invasiveness by increasing matrix
metalloproteinase (MMP) expression. Furthermore, hypoxia stimulation in VHL-reconstituted cell lines increased HIF
isoforms and HDAC1 expression. Presence of hypoxia response elements in the HDAC1 promoter along with
chromatin immunoprecipitation data suggests that HIF-2α is a transcriptional regulator of HDAC1 gene. Conversely,
HDAC6 and estrogen receptor alpha (ERα) were co-localized in cytoplasm of ccRCC cells and HDAC6 enhanced cell
motility by decreasing acetylated α-tubulin expression, and this biological effect was attenuated by either
biochemical or pharmacological inhibition. Finally, analysis of human ccRCC specimens revealed positive correlation
between HIF isoforms and HDAC. HDAC1 mRNA upregulation was associated with worse overall survival in the
TCGA dataset.
Conclusions: Taking together, these results suggest that HDAC1 and HDAC6 may play a role in ccRCC biology and
could represent rational therapeutic targets.
Background
Inactivation of the tumor suppressor gene von Hippel
Lindau, VHL, is a common alteration in sporadic clear
cell renal cell carcinomas (ccRCCs) [1]. VHL protein is
responsible for the proteasomal degradation of hypoxia
inducible factors (HIF) by binding to the oxygen
dependent domain on HIF, thus inhibiting downstream
target genes involved in angiogenesis, glycolysis and cell
cycle [2–4].
Histone deacetylases (HDACs), enzymes that regulate
chromatin status and gene expression, are subdivided
into four classes (I, II, III and IV), based on their struc-
ture [5]. In ccRCC, class I HDACs (i.e. HDAC 1 and
HDAC 2) have been reported to be overexpressed, as
compared to adjacent non-tumor tissues [6]. Our lab has
shown that class II HDACs, HDAC 4 and HDAC 6,
stabilize HIF-1α in renal and prostate tumor cells [7, 8].
However, studies related to the regulation of HDAC
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expression and the role of HDACs in ccRCC tumor biol-
ogy remain limited.
Class I HDACs, specifically HDAC 1, is upregulated at
both the mRNA and protein level under hypoxic condi-
tions, which corresponds to increased HDAC activity
that can be blocked by the HDAC inhibitor (HDACi) tri-
chostatin A (TSA) [9]. Class I HDACs further regulate
HIF-1α stability, and TSA abrogates this effect in HeLa
cells [10]. The pan HDACi panobinostat downregulates
HIF-1α protein in HUVECs as well as in prostate cancer
cell lines under normoxic and hypoxic conditions [11].
The class II HDAC 6 increases invasiveness and motility
in kidney epithelial cells through deacetylation of α-
tubulin, which is counteracted by a specific HDAC 6 in-
hibitor (tubacin) and TSA [12]. HDAC 6 translocation
to the plasma membrane is associated with membrane
estrogen receptor alpha (ERα), and deacetylation of α-
tubulin increases motility of breast tumor cells in vitro
[13]. HDAC 6 upregulation in MCF7 cells changed the
morphological features as well as the migration capacity
of these cells [14]. In addition, estrogen receptor (ER)-
positive tumors with concomitant HDAC 6 overexpres-
sion showed significant increase in overall and cancer
specific survival after tamoxifen treatment [14]. Early
evidence for the expression of ERα in kidney tumors has
been demonstrated in an estradiol-induced hamster kid-
ney tumor model that showed the presence of ERα in
epithelial tumor cells and stromal cells in both female
and male hamsters [15].
There are several studies involving the combination of
HDAC inhibitors and ERα antagonists in breast cancer.
In ER-positive tumors, panobinostat increases cell death
in synergy with hydroxytamoxifen [16], whereas valproic
acid in combination with tamoxifen augmented the in-
hibition of cell proliferation and apoptosis [17]. TSA also
enhanced the effectiveness of hormonal therapy in ER-
negative breast tumors through ERβ activity [18]. Add-
itionally, RCC cells when treated with estrogen showed
decreased proliferation, migration and invasion of cells,
primarily through ERβ effects [19].
In this study, we investigated the role of class I and II
HDACs in ccRCC tumor biology by utilizing in vitro
models and human samples.
Methods
Cell lines, treatments and antibodies
Renal cell lines C2, C2VHL and 786–0 were kindly pro-
vided by Drs. Jennifer Isaacs and Len Neckers (National
Cancer Center). Cells were cultured in DMEM media
supplemented with 10 % FBS at 37 °C and 5 % CO2 con-
centration. 5x105 cells in duplicate 12-well plates were
serum-starved for 24 h followed by treatment with
media/10 % FBS with or without the hypoxia. Cobalt
chloride (100 μM) (Sigma Aldrich, Cat.no. 232696)
addition for 24 h was used as hypoxia mimic in these
studies. At the designated time point, cells were har-
vested in RIPA buffer (Sigma Aldrich, Cat. no. R0278)
with protease and phosphatase inhibitors (Roche) for
western blot. For short term effects on the levels of acet-
ylated alpha tubulin, 3000 cells were plated on coverslips
overnight, followed by treatment with hydroxytamoxifen
(Sigma Aldrich, Cat. no. T176) and/or panobinostat
(Novartis) for 4 h. Antibodies against HIF-1α (Cayman
chemical, Cat.no. 10006421), HIF-2α (Abcam, Cat.no.
ab199), HDAC 1 (Cell signaling, Cat.no. 5356), acety-
lated H3 (Millipore, Cat.no. 06–599), HDAC 6 (Santa-
cruz Cat. no. sc-11420), ER-alpha (Santacruz, Cat. no.
sc-543), acetylated α-tubulin (Life technologies, Cat. no.
32–2700), total histone H3 (Cell signaling, Cat.no. 9715),
GAPDH (Cell signaling, Cat. No. 2118), and HRP-
conjugated rabbit (BioRad, Cat.no. 170–6515) and
mouse (Dako, Cat.no. P0260) secondary antibodies were
used at the recommended dilutions.
Western blot analysis and flow cytometry
Cells were harvested using RIPA buffer for Western blot,
and 40 μg of total protein were run on 12 % gels
followed by wet transfer at 25 V overnight at room
temperature. The blots were then blocked with 10 %
milk, followed by incubation with primary antibody and
HRP-conjugated secondary antibody. Protein bands were
detected with ECL (Perkin Elmer, Cat.no.
NEL105001EA). 8x105 cells were plated for flow cytome-
try, treated and harvested for fixation and
permeabilization (BD Pharmingen, Cat. no. 560409).
Cells were blocked with blocking serum, incubated with
HDAC 1 antibody, washed, incubated with secondary
FITC-conjugated anti-mouse antibody (BD bioscience,
Cat.no. 554001) and finally stained with propidium iod-
ide for cell cycle analysis. Cells were run on a LSR For-
tessa, and results were analyzed using FCS Express
software.
Transfections
The wt-VHL plasmid was kindly provided Dr. Michael
Ohh (University of Toronto) and transfected into 786–0
cells with Lipofectamine 2000 (Life technologies, Cat.no.
11668–019) and OptiMEM media (Life Technologies,
Cat. no. 31985070). The following day, cells were incu-
bated with media containing neomycin and selected for
two weeks for stable transfection. The HDAC 6 plasmid
(kindly provided by Dr. Tso Pang Yao at Duke Univer-
sity) and the HDAC 1 shRNA were transfected and
packaged in retroviral cells at the RPCI genomics core
facility. Retroviral supernatants were added to C2 and
786–0 cells, spun for 45 min at 1800 rpm and incubated
for 4 h at 37 °C. Regular medium was then added to the
cells, and puromycin (for HDAC 1 knockdown selection)
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or neomycin (for HDAC 6 selection) was added for se-
lection the next day. Cells that were infected were se-
lected for a period of two weeks. HDAC 1 and HDAC 6
knockdown was observed by Western blot and immuno-
fluorescent analysis, respectively. For HIF-2α knock-
down, shRNA against HIF-2α was purchased from
Addgene (Plasmid 22131) and transfected using retro-
viral supernatants generated at the RPCI genomics core
facility. The next day, cells were incubated with regular
media and selected with neomycin for a period of two
weeks. The cells were tested for HIF-2α knockdown effi-
ciency by Western blot analysis. For ERα knockdown,
siRNA against ERα was transfected using Lipofectamine
2000 in OptiMEM media. The cells were tested for ERα
knockdown efficiency by Western blot, and acetylated α-
tubulin levels were measured by immunofluorescence.
Proliferation and Invasion assay
For proliferation assays, 8x103 cells were plated in
24 well plates with regular media and harvested after
24, 48 and 72 h for measurement of proliferation by
staining the wells with crystal violet. This was
followed by dissolution of the stain in methanol for
2–3 h, and the plates were read at 590 nm. Prolifer-
ation at different time points was compared to 24 h
for growth rate calculations. For invasion assays,
5x105 cells were plated on top of Matrigel-coated
chambers (BD bioscience, Cat.no. 354480) in regular
medium with serum overnight. The medium on top
was replaced with serum free media the next day,
and media with serum was added to the bottom of
the well as a chemoattractant. The non-invading
cells at the top of the chamber were removed with
cotton swabs (after 4 h for 786–0 cells and 24 h for
C2 cells), and cells on the lower surface were stained
with crystal violet (Sigma Aldrich, Cat. no. HT
90132) for 30 min. The inserts were washed thrice
with distilled water, and the number of invading cells
were counted by observation under the microscope.
The HDAC 1 knockdown cells were compared to
the parental cell lines for measuring invasion cap-
ability. In addition, a gelatin zymography assay was
performed to analyze the matrix metalloprotease
(MMP) activity in the cell lysate as well as in the
supernatant. Briefly, 5x104 cells were plated in a 24-
well plate in regular DMEM with serum for 24 h.
This was followed by media change to DMEM with-
out serum (to analyze MMP activity in the cell
supernatant) for 16 h. Cell supernatants and cell ly-
sates (harvested by RIPA Buffer) were collected at
the end of the experiment. The lysates and superna-
tants were then run on 7.5 % acrylamide gels with
1 % gelatin (substrate for MMP); followed by incuba-
tion with renaturing buffer for 30 min, developing
buffer overnight at 37 °C, stained with commassie
blue for 30 min, and finally destained with destain-
ing solution until the bands on the gel were strong
and clear.
Immunofluorescence assay
After treatments, cells were fixed in 4 % formaldehyde,
followed by permeabilization with Triton-X 100 (Sigma
Aldrich; Cat. no. T8787) and blocking with 1 % bovine
serum albumin for one hour. The cells were stained for
acetylated α-tubulin, HDAC 6 and ERα and detected by
secondary FITC or Alexa-fluor tagged secondary anti-
body. Zeiss AxioImager and the axiovision software were
used to capture immunofluorescent images at 20X mag-
nification. Immunofluorescent images were analyzed
using the NIH software Image J. Integrated density of
images was calculated using Image J and plotted as bar
graphs for comparison of intensity of fluorescence in
images.
Motility and migration assay
5x105 cells were plated in a 12-well plate overnight to
develop a monolayer, followed by creating a horizontal
scratch in the plate using a sterile pipette tip. The cells
were then placed in fresh media and observed over a
period of 24 h. A grid was developed for the 12-well
plate to maintain the same field of observation for cell
motility.
Analysis of HDAC 1 promoter and non-promoter region
by Chromatin immunoprecipitation assay
1x106 cells were plated in 10 cm2 culture dishes over-
night, and the ChIP protocol from Novus was followed.
Briefly, cells were fixed with 1 % formaldehyde (Sigma
Aldrich, Cat. no. 252549), and 125 mM glycine (Sigma
Aldrich, Cat.no. G8898) was added to the media for
quenching, followed by washing with PBS and harvesting
of the cells with RIPA buffer. The samples were then
sonicated for twelve 15 s pulses at a 50 % output with a
60 s rest on ice, centrifuged to remove debris, and then
incubated with HIF-1α, HIF-2α or corresponding Ig
antibodies overnight. Magnetic Protein G beads (Invitro-
gen, Cat.no. 10003D) were added to the samples over-
night at 4 °C, washed and eluted with IP elution buffer
and finally incubated with proteinase K overnight at 62 °
C. cDNAs were isolated with Phenol/chloroform/isoamyl
alcohol followed by qPCR of immunoprecipitated sam-
ples. Input control and percent input were calculated
and compared with Ig controls. Primers used for qPCR
analysis were as follows:
HDAC 1 promoter region: Forward primer: 5’-
GACCGACTGACGGTAGGGA-3’, Reverse primer: 5’-
GGTGCTCACCGTCGTAGTAG-3’
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HDAC 1 non-promoter region: Forward primer: 5’-
GAGTGTGCAGGTTCTGCTCT-3’, Reverse primer:
5’-CACACCCAGCCAGACTGAAT-3’
VEGF promoter region: Forward primer: 5’-
GATCTGTGTGTCCCTCTCCC-3’, Reverse primer: 5’-
AAAGTGAGGTTACGTGCGGA-3’
Immunohistochemistry and Immunofluorescence of TMA
A small cohort of TMAs was established in the lab with
ccRCC that were collected immediately after nephrec-
tomy, deidentified by the tissue procurement core at
RPCI and received by the lab. The tissues were fixed in
formalin, placed in a multi-tissue cassette, paraffin em-
bedded and used for HDAC 1 and HDAC6/ERα staining.
A larger cohort of patients obtained from the pathology
core facility containing 120 ccRCC (GuCa2) and 88
metastatic ccRCC (GuCa4), were additionally analyzed
for HDAC 1 expression. For TMAs and paraffin embed-
ded formalin fixed tissue, the slides were first deparaffi-
nized in xylene and decreasing concentrations of
ethanol; antigen retrieval was carried out by boiling the
slides in 10 mM sodium citrate in a microwave. The
slides were washed, incubated with 3 % hydrogen perox-
idase to inhibit peroxidase activity, blocked with horse
serum (Vector Laboratories, Cat. no. S1000) and incu-
bated with HDAC 1 or HDAC 6/ERα primary antibody
overnight. For immunohistochemistry, slides were
washed the next day, incubated with secondary HRP-
conjugated antibody (Vector Laboratories, Cat. no.
MP7401) followed by incubation with DAB (Dako, Cat.
no. 3467), hematoxylin counterstaining, dehydration and
mounting on coverslips using cytoseal. For immuno-
fluorescence, slides were washed the next day, incubated
with secondary antibodies conjugated to fluorochromes,
followed by incubation with DAPI for nuclear staining
and mounted on coverslips using Vectashield. Brightfield
and fluorescent images were taken on Zeiss microscope
with Axiovision software. HIF-1α and HIF-2α status in
the TMA was obtained from Chintala et al. [19] and cor-
related with HDAC 1 status in these tumors.
Statistical analyses
The outcomes measures (HDAC expression, cell counts,
acetylated α-tubulin levels, and qPCR data) of the
in vitro studies are reported by experimental group using
the mean and standard deviation; and graphically using
dot- or mean-plots. Comparisons are made between ex-
perimental groups using the paired T-test (when com-
paring expression between tumor and adjacent non-
tumor tissue) and the two-sample Student’s T-test or
one-way ANOVA, as appropriate. In the TMA samples,
the association between the HDAC expression and HIF-
1α/HIF-2α status was assessed using one-way ANOVA;
and reported graphically using box-plots. The association
between HDAC expression and tumor stage (T1-2 versus
T3-4) or grade (I/II versus III/IV) was assessed using the
Student’s T-test. The survival outcomes (overall, disease-
specific, and progression-free survival) were summarized
by HDAC mRNA status (unaltered versus upregulated)
using standard Kaplan-Meier methods, with comparisons
made using the log-rank test. Analyses were completed in
SAS v9.4 (Cary, NC) at a significance level of 0.05; there-
fore a p-value less than 0.05 is considered statistically
significant.
TCGA data analysis
cbioportal website was used to analyze the TCGA
ccRCC provisional database [20, 21]. ccRCC tumors with
HDAC 1 and HDAC 6 overexpression were selected for
overall and progression free survival.
Ethics statement
All patients gave written informed consent for the col-
lection of biomaterials. The study was approved by the
Genitourinary Disease Site Research Group at Roswell
Park Cancer Institute (number: BDR 036713).
Results
Class I and II HDACs are overexpressed in a subset of
ccRCC tumors
To assess the expression of class I and II HDACs, we ex-
amined a set of ccRCC tumors and compared them to
adjacent non-tumor tissue. Western blots were semi-
quantified through Image J analysis, and HDAC band
density in tumor tissue was normalized to its expression
in the adjacent tissue for comparative analysis. As previ-
ously reported [6], class I HDAC expression was gener-
ally upregulated in ccRCC when compared to the non-
tumor tissue (Fig. 1a and b). Interestingly, class II
HDACs were downregulated in most of the tumor sam-
ples, but HDAC 6 was overexpressed in a small subset
of ccRCC patients (Fig. 1c and d).
HDAC 1 and HDAC 6 increase invasion and motility of
renal tumor cell lines in vitro
To assess the biological role of HDAC 1, we knocked
down its gene expression in VHL-null renal tumor cell
lines, and selected the clones that displayed the most ef-
ficient HDAC 1 protein knockdown (Fig. 2a). Surpris-
ingly, the inhibition of HDAC 1 gene expression did not
have significant effects on cell proliferation (data not
shown). To analyze whether HDAC 1 knockdown af-
fected the invasive capacity of the cells, we utilized BD
biocoat matrigel chambers and counted the tumor cells
that migrated through the membrane. The studies con-
ducted with 786–0 and C2 renal cancer cell lines showed
that knockdown of HDAC 1 led to reduced invasive cap-
acity (Fig. 2b and c). The effect of HDAC 6 on cell
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motility was measured by scratch assays. C2 cells over-
expressing HDAC 6 (C2H6) had increased motility at
24 h after scratching, as compared to the parental cell
lines (Fig. 2d and e). 786–0 cells had higher motility
than the other cell lines, as indicated by the faster
scratch closure at 24 h (Fig. 2e).
HDAC 1 and HDAC 6 increase invasiveness and motility
through increased MMP2/9 activity and decreased
acetylated α-tubulin, respectively
Class I HDACs increase invasive through increased
MMP activity in different cancer cell lines [22–24].
Therefore, we analyzed the metalloproteinase and α-
tubulin acetylation activity under our experimental con-
ditions. Gelatin zymography assays revealed that HDAC
1-knockdown cells had lower MMP activity in both the
supernatant and cell lysates (Fig. 3a). Interestingly, the
Broad-Novartis cancer cell line encyclopedia of gene
expression analysis of renal tumor cell lines shows that
786–0 cells indeed have higher HDAC 1 gene expression
as compared to the C2 cells, with a corresponding in-
crease in MMP-2/9 gene expression (Additional file 1:
Figure S1). We also measured acetylated α-tubulin in
HDAC 6-overexpressing and parental cells using an im-
munofluorescence assay. HDAC 6-overexpressing cells
(C2H6) showed lower acetylated α-tubulin intensity as
compared to parental C2 cells (Fig. 3b and c). In
addition, 786–0 cells showed high HDAC 6 activity, as
evidenced by lower acetylated α-tubulin levels (Fig. 3b
and c).
HIF-α regulates HDAC 1 expression in renal cell lines
in vitro
To determine whether the VHL-HIF axis regulates
HDAC 1 expression, we generated two isogeneic RCC







Fig. 1 Class I and II HDACs are overexpressed in a subset of ccRCC tumors. Tissues from ccRCC tumors and adjacent non tumor tissues were
homogenized and 50 μg of total protein was analyzed by Western blot for the expression of class I and II HDACs. a) Semi-quantitative analysis of HDAC
bands were performed in Image J. Each tumor was normalized to GAPDH before normalizing it to their respective non-tumor tissue. b) Representative
Western blots of two different matched tumor and non-tumor tissues show differential expression of class I HDACs. c) Semi-quantitative analysis of HDAC
bands were performed in Image J. Each tumor was normalized to GAPDH before normalizing it to their respective non-tumor tissue. d) Representative
Western blots of two different matched tumor and non-tumor tissues show differential expression of class II HDACs. The dotted line at 1 indicates the
expression of HDAC 1 in adjacent non-tumor tissue. *p< 0.05 indicates statistically different HDAC 2 protein expression in tumor tissues as compared to
the non-tumor tissue
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expression. Western blot analysis revealed that HDAC 1
was differentially expressed in renal tumor cell lines with
wild type and non-functional VHL in vitro (Additional
file 1: Figure S2a). VHL-null cells showed higher HDAC
1 expression levels, as compared to their wild type VHL
counterparts. This increase in HDAC 1 expression was
also associated with greater HIF expression in VHL-null
cell lines (Additional file 1: Figure S2a). The reintroduc-
tion of VHL in both cell lines, however, did not signifi-
cantly alter the proliferation rate (data not shown). C2
cells displayed constitutive expression of HIF-1α and
minimal expression of HIF-2α at 24 h (Additional file 1:
Figure S2a). This constitutive expression of HIF-α was






Fig. 2 HDAC 1 and HDAC 6 increase cell invasion and migration in RCC cells, respectively. HDAC 1 was knocked down in 786–0 and C2 cells
using retroviral supernatants. a) Three different clones with HDAC 1 knock down were generated and Sh2 was chosen in both cell lines for
further experiments. b) BD biocoat matrigel chambers were used for measuring the invasion capacity of parental and HDAC 1 knocked down
cells. C2 cells were incubated in the chamber for 24 h, whereas 786–0 cells were incubated for a short time point of 6 h. Cells at the bottom of
the wells were visualized by crystal violet staining. c) Cells at the bottom of the well were counted blindly using a bright field microscope.
*p < 0.05 indicates statistically different number of cells in shHDAC1 cells as compared to the parental cells. The error bars represent standard
errors from biological triplicate experiments with technical replicates within each experiment. d) Representative images of renal tumor cell lines
analyzed for HDAC 6 expression by immunofluorescence are shown. Scale bar indicates 50 μM distance and images are taken at 20X
magnification. e) Representative images of scratch assays performed on C2, C2 overexpressing HDAC 6 and 786-O cells at time 0 and at the end
of 24 h are shown
Ramakrishnan et al. BMC Cancer  (2016) 16:617 Page 6 of 15
(Additional file 1: Figure S2a). In addition, upregulation
of HDAC 1 protein expression in C2VHL cells by hyp-
oxic stimulation was associated with an increase in
HDAC 1 activity (measured by the levels of acetylated
histone H3) (Fig. 4a and Additional file 1: Figure S6a-c).
Similarly, HDAC 1 protein expression was induced by
hypoxic mimetic agent cobalt chloride treatment in 786-
0VHL cells (Additional file 1: Figure S2b). For quantita-
tive analysis of protein expression, HDAC 1 protein
levels in the different cell lines were measured by flow
cytometry under both normoxic and hypoxic conditions.
The HDAC 1 levels were measured as percentage of
cells that were positive for HDAC 1 (tagged with FITC),
as observed in the flow cytometry data. A representative
image of the flow cytometry data illustrates an induction
of HDAC 1 expression in the wt-VHL cells upon hyp-
oxic stimulation (Additional file 1: Figure S2c and d). In
accordance with our observation, the genomatix soft-
ware showed the presence of hypoxia response elements
(HREs), as represented by RCGTG, in the HDAC 1 pro-
moter region upstream of the transcription start site
(Fig. 4b). Interaction between HDAC 1 and HIF isoforms
were evaluated by chromatin immunoprecipitation




Fig. 3 HDAC 1 and HDAC 6 increase MMP-2/9 activity and decrease acetylated α-tubulin levels, respectively. a) C2 and 786–0 parental and knocked down
HDAC 1 were analyzed for MMP activity by gelatin zymography assay. MMP activity was measured both in cell lysates as well as cell supernatants. b) Renal
tumor cell lines were analyzed for HDAC 6 and acetylated α-tubulin expression by immunofluorescence. The staining in red indicates acetylated α-tubulin
and the staining in green indicates HDAC 6 expression. Scale bar indicates 50 μM distance and images are taken at 20X magnification. c) Image J analysis
measured immunofluorescence by calculating integrated density values of at least three representative fields per cell line. *p< 0.05 indicates statistically
significant difference in acetylated α-tubulin levels as compared to C2 cells. The error bars represent standard errors from triplicate experiments and p-value
was calculated using students t-test





Fig. 4 (See legend on next page.)
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expression. In C2 cells, both HIF-1α and HIF-2α pull
downs were enriched for the HDAC 1 promoter re-
gion, as analyzed by qPCR (Fig. 4c and d). The HIF-
2α only cell line, 786–0, also demonstrated enrich-
ment for the HDAC 1 promoter region upon HIF-2α
pull down (Fig. 4e). VEGF is a known target of both
HIF isoforms, and VEGF promoter primers were used
as positive control for ChIP assays to detect effective
pull downs for HIF (Fig. 4c-e). In order to explore
the possibility of HIF-2α playing a dominant role in
regulating the expression of HDAC 1, HIF-2α was
knocked down in both C2 and 786–0 cells. Silencing
of HIF-2α in both cell lines dramatically reduced the
protein levels of HDAC 1 that corresponded to in-
creased acetylated histone H3, indicating loss of
HDAC 1 activity in these cells (Fig. 4f and Additional
file 1: Figure S6d-f ).
ER-α regulates acetylated α-tubulin levels in renal tumor
cells in vitro through its interaction with HDAC 6
HDAC 6 increases motility by deacetylation of α-
tubulin and this increase is associated with ER-α ex-
pression in breast tumor cell lines [13]. Both HDAC
6 and ERα protein are expressed in ccRCC tumors, as
measured by Western blot analysis (Fig. 5a). We fur-
ther analyzed the subcellular location of HDAC 6 and
ERα in ccRCC tumors and found that both HDAC 6
and ERα are expressed in the cytoplasm of these tu-
mors in a punctuated format (Fig. 5b). We knocked
down ERα expression in 786–0 and C2 cells (labeled
as 786-OsiER and C2siER) to evaluate the role ERα
in maintaining the deacetylated status of α-tubulin.
The ER-positive breast cancer cell line MCF7 was
used as a positive control for ERα. By using a siRNA
pool mammalian vector, were able to successfully re-
duce ERα expression not only in the breast cancer
cell line, but also the in the renal cell lines (Fig. 5e).
ERα knockdown led to increased acetylated α-tubulin
levels in both 786–0 and C2 cells, as observed by im-
munofluorescence (Fig. 5c-f ). ERα silencing did not
have an effect on HDAC 6 expression (as measured
by integrated density of immunofluorescent images)
(Fig. 5f ). However, silencing ERα did not affect the
proliferation rate of these cells (data not shown).
Then, we treated C2, C2H6 and 786–0 cells with
10 μM hydroxytamoxifen and 50nM panobinostat
(class I and class II HDAC inhibitor) for 4 h to
analyze the effect of pharmacological inhibition of
ERα and HDAC 6 on the levels of acetylated α-
tubulin. We found that hydroxytamoxifen alone was
able to increase acetylated α-tubulin, and the com-
bination with panobinostat intensified this effect
(Fig. 5g-h, Additional file 1: Figure S3a-d). In C2H6
but not in parental C2 cells, single and combination
treatments increased HDAC 6 expression (Fig. 5h,
Additional file 1: Figure S3b). Similarly, in 786-O
cells single and combination treatments increased
both HDAC 6 and ERα expression. However this in-
crease in expression did not result in an increased
HDAC 6 activity as measured by the presence of
acetylated α-tubulin.
HDAC 1 expression correlates with HIF expression in
ccRCC and is associated with poorer survival
We next interrogated a tissue microarray (TMA) con-
sisting of matched tumor and adjacent non-tumor tissue
for HDAC 1 expression and its correlation with HIF iso-
forms, as previously described [25] (Fig. 6a). Statistical
analysis indicates that tumors that were HDAC 1-
positive were more likely to be double positive for HIF-
1α/HIF-2α (Fig. 6b). Surprisingly, however, HDAC 1 was
not associated with tumor grade, overall survival or dis-
ease specific survival (data not shown). Furthermore,
there was no association between survival status and ei-
ther HIF isoforms in this cohort of tumors (data not
shown). However, HDAC 1 mRNA upregulation is
present in 4 % of the patients in the TCGA data set [20,
21] and it is associated with worse overall survival
(Fig. 6c-d). Both HDAC 1 and HDAC 6 mRNA upregula-
tion are associated with higher tumor stage, though
these differences are not statistically significant (Add-
itional file 1: Figure S4a and b) [20, 21].
(See figure on previous page.)
Fig. 4 HDAC 1 expression is regulated by HIF in RCC cell lines. a) HDAC 1 expression was compared between C2 and C2VHL cells under
normoxic and hypoxic conditions (mimicked by the use of 100 μM cobalt chloride) after overnight serum starvation. The numbers below the
bands represent densitometry performed by Image J analysis on representative immunoblots relative to C2 bands in normoxic conditions with
total histone H3 serving as loading control. b) HDAC 1 promoter region was analyzed for the presence of hypoxia response elements (HREs) by
using the genomatix software. HREs represented by RCGTG and are highlighted in yellow and the black arrow represent the location of the
forward and reverse primer. c-e) Chromatin immunoprecipitation assays were carried out in VHL null cell line C2 that expressed both HIF isoforms
and 786–0 that only expressed HIF-2α. Pull downs with HIF isoforms were analyzed for HDAC 1 promoter/non-promoter region (1 kb upstream of
the transcription start site) and the VEGF promoter (a known target of HIF) by qPCR. The error bars represent standard errors from biological
duplicate experiments with technical replicates within each experiment. f) HIF-2α was knocked down in both models of renal cell line tumors by
mammalian shRNA and analyzed for HDAC 1 expression and acetylated histone H3 by Western blot. The numbers below the bands represent
densitometry performed by Image j analysis on representative immunoblots relative to parental cell lines in normoxic conditions with total
GAPDH serving as loading control








Fig. 5 (See legend on next page.)
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HDAC 6 is associated with worse overall survival and
progression free survival in TCGA data set
Although not statistically significant, HDAC 6 mRNA
upregulation (in 9 % of tumors) was associated with
worse overall survival and progression free survival in
ccRCC patients (Additional file 1: Figure S5a-d) [20, 21].
Discussion
In this study, we report that HDAC 1 and HDAC 6
modulate the motility and invasion of RCC cells in vitro
through the regulation of matrix metalloproteases
(MMPs) and acetylated α-tubulin, respectively (Fig. 7).
In addition, we observed that HIF-α regulates HDAC 1
expression, while HDAC 6 and ERα increase α-tubulin
deacetylation. In addition, HDAC 1 expression is associ-
ated with HIF overexpression in ccRCC tumors, and
HDAC 1 mRNA upregulation in TCGA data set is asso-
ciated with poor outcome. HDAC 6 mRNA upregulation
is also associated with shorter overall and progression
free survival, although not statistically significant. Taken
together, these results suggest that HDACs may play a
role in the aggressiveness of ccRCC and that a subset of
these tumors may be targetable with HDAC inhibitors.
The VHL tumor suppressor gene is deregulated in ap-
proximately 70 % of the sporadic cases of ccRCC, and its
major role is to decrease the stability of HIF isoforms
under normal oxygen levels [3, 26–28]. The VHL-HIF
axis deregulation has been implicated in the activation
of several oncogenic pathways in ccRCC [29–31]. HIF
isoforms are stabilized by histone deacetylases and can
be antagonized by the use of HDAC inhibitors [7, 10,
32]. However, there have been only a few studies asses-
sing the role of HIF isoforms in regulating HDAC ex-
pression and activity. A subset of ccRCC tumors
overexpresses class I and II HDACs when compared to
adjacent non-tumor tissues. Class I HDACs, HDAC 1
and HDAC 2, have been shown to increase invasion
through the upregulation of MMP-2 and MMP-9 in dif-
ferent cancer cell lines [22, 24, 33]. TSA exhibits anti-
invasive properties through upregulation of RECK,
which further inhibits MMP-2 and MMP-9 in a variety
of cell lines, including breast cancer cell lines and hepa-
tocytes, amongst other cancer types [23, 24]. Our study
demonstrates that HDAC 1 knockdown reduces the in-
vasive capacity of renal tumor models through decreased
MMP activity in these cells. On the other hand, HDAC
6 is known to be overexpressed in different tumor types,
to have oncogenic functions and to interact with other
pathways to enhance tumorigenesis [34–37]. 786–0 cells
were associated with lower acetylated α-tubulin, suggest-
ing increased HDAC 6 activity as compared to C2 cells.
The clinical relevance of this is not yet fully understood;
however, the 786–0 cells are thought to represent a
more aggressive type of ccRCC as compared to C2 cells.
Upon enhancing HDAC 6 activity in the C2 cells by
using an overexpression system, we observed that
HDAC 6 was associated with not only decreased acety-
lated α-tubulin levels but also with functional conse-
quences in terms of enhanced cell motility. Thus, it can
be speculated that those tumors with higher HDAC 1 or
HDAC 6 expression have a potential to be more aggres-
sive as well as more metastatic in the clinical setting.
Further investigation of the regulation of HDAC 1
revealed a possible role of HIF isoforms in ccRCC cell
lines. When comparing VHL-null cell lines with wild
type VHL cell lines of renal tumor models, HDAC 1
expression was found to be upregulated in VHL-null
cell lines. In addition, hypoxia stimulation of wt-VHL
cells led to both HIF and HDAC 1 upregulation.
Chromatin immunoprecipitation assay findings
showed that the HDAC 1 promoter region is enriched
upon pull down of both HIF isoforms and knock-
down of HIF-2α in renal tumor cell lines reduced
HDAC 1 expression in these cells. HDAC 1 activity
as measured by acetylated histone H3 is also affected
in these cell lines. Therefore, the above results indi-
cate that HIF is involved in the regulation of HDAC
1 protein expression and activity. To date, anti-
angiogenic drugs and agents inhibiting the mTOR
pathway have been extensively studied in ccRCC
treatment. Targeting HDACs in ccRCC, therefore, has
the potential to reduce not only HDAC activity but
(See figure on previous page.)
Fig. 5 Acetylated α-tubulin is regulated by HDAC6/ER-α interaction in RCC cell lines. a) HDAC 6, ER-α and acetylated α-tubulin protein expression were
measured by western blot analysis in ccRCC tumors and adjacent non-tumor tissue. b) A representative ccRCC tumor showed HDAC 6 (in red) and
ER-α (in green) localization in the cytoplasm. c-d) Representative immunofluorescent images of acetylated α-tubulin (in red) and HDAC 6 (in green)
expression in parental and ER-α knockdown cell lines are shown. e) Knockdown of ER-α in MCF-7 and renal cell tumors as measured by Western blot
analysis. f) Image J analysis measured immunofluorescence by calculating integrated density values of at least three representative fields per cell line.
*p < 0.05 and **p < 0.01 indicates statistically significant difference of acetylated α-tubulin levels in ER-α knockdown cells as compared to the parental
cell lines. The error bars represent standard errors from triplicate experiments and p-value was calculated using students t-test. g) C2H6 cells treatment
with 10 μM hydroxy tamoxifen and/or 50nM panobinostat for 4 h. Representative immunofluorescence images of acetylated α-tubulin (in red), HDAC
6 (in green) and ER-α (in green) are shown. h) Image J analysis measured immunofluorescence by calculating integrated density values of at least three
representative fields per cell line. *p < 0.01 indicates statistically different HDAC 6 levels in treated cell lines as compared to control cells. The error bars
represent standard errors from biological triplicate experiments with technical replicates for each experiment. Scale bar indicates 50 μM distance and
images are taken at 20X magnification
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also reduce HIF stability. This may further decrease
HDAC expression and activity by HIFs.
The examination of ccRCC tumor samples obtained
by nephrectomies demonstrated overexpression of
HDAC 6 in a subset of tumors along with ERα expres-
sion. This phenomenon occurs regardless of the gender
of the patient, indicating that ERα may have a potential
role in the biology of ccRCC tumors. By immunofluores-
cent microscopy analysis of the expression of these pro-
teins in the tumor, both ERα and HDAC 6 were present
exclusively in the cytoplasm. In breast cancer, the
colocalization of HDAC 6 and ERα in the cytoplasm has
been associated with better clinical outcome in
tamoxifen-treated patients as well as increased deacety-
lation of α-tubulin, which led to enhanced cell motility
in vitro [13, 14]. Thus, we carried out ERα knockdown
assays to examine the putative role of ERα in renal
tumor cell lines, in particular the role on deacetylation
of α-tubulin. Knockdown of ERα in renal tumor cell
lines drastically increased the levels of acetylated α-
tubulin, confirming that both HDAC 6 and ERα regulate
the levels of acetylated α-tubulin and, thus, play roles in




Fig. 6 HDAC 1 and HIF positively correlate in clinical ccRCC. a) HDAC 1 expression in TMA was examined by immunohistochemistry. HDAC 1 positive
nuclei were quantitated using Image J software and percent positive nuclei (indicated by brown staining) were used for further analysis. Black arrows
indicate positive nuclei that were identified by the Image J software. The scale bar indicates 200 μM and the image was captured at 4X using the
Aperio software. b) The association between HDAC1 and HIF1 & HIF2 statuses was examined using Wilcoxon rank sum and Kriskall-Wallis exact tests.
All analyses were conducted in SAS v9.3 (Cary, NC) at a significance level of 0.05. c) Kaplan Meir curves (overall survival) of unaltered and upregulated
HDAC 1 mRNA levels in the TCGA data are shown. The blue line indicates unaltered HDAC 1 mRNA and the red line indicates upregulated HDAC 1
mRNA levels. d) The table shows the numbers of patients in each group and survival data in months
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regulating the motility of these cells. Thus, the HDAC
6/ER-α interaction represents a potential therapeutic
target, for reducing the metastatic potential of ccRCC.
Pharmacological inhibition of HDAC 6 and ERα in
renal tumor cell lines showed similar effects as ERα
knockdown in these cells. Tamoxifen showed en-
hanced effects on α-tubulin acetylation in 786–0 cells,
and this effect was greater with the addition of pano-
binostat. Single agent and combination treatments in-
creased HDAC 6 and ER-α expression in C2H6 and
786-O cells; however this did not result in increased
HDAC 6 activity. The mechanisms of increased ERα
and 786-O expression by treatments are not entirely
known. These results indicate that in ccRCC, tamoxi-
fen treatment may reduce metastatic potential. Fur-
thermore, when combined with an HDAC inhibitor,
such as panobinostat (that has cytotoxic effects), can
lead to both anti-tumor effects and reduced metasta-
sis. Moreover, in 100 ccRCC tumors, HIF-1/2α and
HDAC 1 positively correlated with one another; how-
ever, HDAC 1 expression did not correlate with over-
all or disease free survival. TCGA data further
revealed that HDAC 1 overexpression is associated
with worse overall survival and higher tumor stage
(not statistically significant). Hence, targeting HDAC
1 by using class I specific HDAC inhibitors may not
only reduce the invasiveness of the disease, but the
level of HDAC 1 itself can be used as a prognostic
indicator in ccRCC. Similarly, HDAC 6 mRNA upreg-
ulation, although not statistically significant, showed a
trend towards worse overall survival as well as higher
tumor stage in ccRCC patients. Therefore, targeting
HDAC 6 using a class II specific HDAC inhibitor
may reduce the motility and aggressiveness of ccRCC
tumors.
Although HDAC inhibitors have shown potential anti-
tumor activities in preclinical models, the clinical devel-
opment of this class of drugs has only achieved moder-
ate success in hematological malignancies and not in
solid tumors. However, these agents have been tested
primarily as single agents in solid tumors and combin-
ation with already-approved therapies have not been ex-
tensively studied. In ccRCC, our lab has previously
shown that the class I HDAC inhibitor, Entinostat, en-
hances immunotherapy [38] and another study demon-
strated synergistic anti-proliferative effects of the
combination of sorafenib with HDAC inhibitors [39].
The subset of ccRCCs that express high levels of HDAC
1 and HDAC 6 may be the most suitable patient popula-
tion for rational combination strategies using HDAC in-
hibitors with other agents.
Conclusions
Our study indicates a potential use for HDAC 1 and
HDAC 6 expression status in identifying a subset of
ccRCC patients who are suitable for treatment with
HDAC inhibitors. Clinical testing of histone remodeling
drugs in rational combination strategies will shed add-
itional light on the potential therapeutic value of this
class of agents in ccRCC.
Additional file
Additional file 1: Figure S1. VHL, HIF, HDAC1 and related gene expression
in renal tumor cell lines. Gene expression analysis of renal tumor cell lines
using the Broad-Novartis cancer cell line encyclopedia show the levels of
players in the VHL-HIF axis. The top row indicates the gene analyzed in
different renal tumor cell lines (in the left most column). Red color indicates
gene upregulation and blue color indicates downregulation of genes in the
renal tumor cell lines. Figure S2. Hypoxia induces HDAC 1 expression in clear
cell renal tumor cell line. a) Parental VHL null cells C2 and 786–0 were
compared to cells with wt-VHL introduced for HIF-1α, HIF-2α and HDAC 1
protein expression. The left panel measures protein expression in C2 isogeneic
cell lines and the right panel measures protein expression in 786–0 isogenic
cell lines. The numbers below the bands represent densitometry performed
by Image J analysis on representative immunoblots relative to their respective
isogeneic VHL null cells with GAPDH serving as a loading control. b) HDAC 1
expression was compared between 786–0 and 786-0VHL cells under normoxic
and hypoxic conditions (mimicked by the use of 100 μM cobalt chloride) after
overnight serum starvation. The numbers below the bands represent
densitometry performed by Image J analysis on representative immunoblots
relative to 786–0 bands in normoxic conditions with total GAPDH serving as
loading control. c-d) HDAC 1 protein expression was quantitatively measured
by flow cytometry under normoxic and hypoxic conditions. *p< 0.05 indicates
statistically different HDAC 1 expression in wt-VHL cells as compared to VHL
null cell lines. The error bars represent standard errors from biological triplicate
experiments with technical replicates within each experiment. e) The figure is
a representative image obtained from flow cytometry. The Y-axis represents
HDAC 1 expression measured by FITC and Y-axis represents cell cycle
measured by propidium idodide. Figure S3. Panobinostat and tamoxifen
treatment increases acetylated α-tubulin in renal tumor cell lines. a-d) C2 and
786–0 cells were treated with 10 μM hydroxy tamoxifen and/or 50nM
panobinostat for 4 h. Representative immunofluorescence images of
acetylated α-tubulin (in red), HDAC 6 (in green) and ER-α (in green) are shown.
Fig. 7 Schema of HDACs, hypoxia inducible factors and ER-α in clear cell
renal cell carcinoma. Our studies show HDAC 1 can be upregulated by
hypoxia inducible factors that is in turn stabilized by class II HDACs. Class
II HDACs, specifically HDAC 6 can interact with ER-α. These interactions
lead to increased motility and invasive capacity of ccRCC cell lines
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Image J analysis measured immunofluorescence by calculating integrated
density values of at least three representative fields per cell line. *p< 0.05
indicates statistically different acetylated α-tubulin levels in treated cells as
compared to the control cells. The error bars represent standard errors from
biological triplicate experiments with technical replicates for each experiment.
Figure S4. HDAC 1 and HDAC 6 mRNA expression are associated with higher
stage of ccRCC. a) HDAC 1 and b) HDAC 6 mRNA levels in the TCGA data set
were measured by RNA-sequencing data. T1-T2 represent lower ccRCC stage
whereas T3-T4 represent higher ccRCC stage where the tumor has invaded
the adjacent organs or metastatic disease. P-values were calculated by using
the students t-test. Figure S5. HDAC 6 expression and overall or progression
free survival. a) Kaplan Meir curves (overall survival) of unaltered and
upregulated HDAC 6 mRNA levels in the TCGA data are shown. The blue line
indicates unaltered HDAC 6 mRNA and the red line indicates upregulated
HDAC 1 mRNA levels. b) Kaplan Meir curves (progression free survival) of
unaltered and upregulated HDAC 6 mRNA levels in the TCGA data are shown.
c-d) The table shows the actual numbers of patients in each group and
survival data/progression free survival data in months. e) COL6A1 protein
expression as measured by RRPA was compared between tumors with
unaltered and upregulated HDAC 6 mRNA levels. Figure S6. Image J
quantitation of western blot shows inverse relation between hypoxia inducible
factors and HDAC 1. a-c) Image J quantitation of western blots show induction
of HIF-1α, HDAC 1 and reduction of acetylated histone H3 in hypoxic
conditions as compared to normoxia in both C2 and 786-O isogenic cell lines.
C2 Normoxia and 786-O Normoxia were used to normalize Image J
quantitation. d-f) Image J quantitation of western blots show reduction in
HDAC 1 and increase in acetylated tubulin upon HIF-2α knockdown in C2 and
786-O cells. C2 control and 786-O control cells were used to normalize Image
J quantitation. Triplicate western blots were plotted with error bars indicating
standard error of mean. *p< 0.05 and **p< 0.01. (PPTX 2954 kb)
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